Literature DB >> 1678803

Reversible thyroid dysfunction during treatment with GM-CSF.

K Hoekman1, B M von Blomberg-van der Flier, J Wagstaff, H A Drexhage, H M Pinedo.   

Abstract

To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250 micrograms/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678803     DOI: 10.1016/0140-6736(91)91103-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Influence of granulocyte-macrophage colony stimulating factor on pituitary-adrenal axis (PAA) in rats in vivo.

Authors:  K Zylińska; S Mucha; J Komorowski; A Korycka; H Pisarek; T Robak; H Stepień
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

3.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

Review 4.  Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant.

Authors:  T Jones; A Stern; R Lin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

5.  Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?

Authors:  G J Locker; I Simonitsch; R M Mader; E Warlamides; M F Gnant; R Jakesz; H Rainer; G G Steger
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

6.  Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha.

Authors:  H Gisslinger; B Gilly; W Woloszczuk; W R Mayr; L Havelec; W Linkesch; M Weissel
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

Review 7.  The side-effect profile of GM-CSF.

Authors:  A C Stern; T C Jones
Journal:  Infection       Date:  1992       Impact factor: 3.553

8.  Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

Authors:  Alessandra De Remigis; Tanja D de Gruijl; Jennifer N Uram; Schey-Cherng Tzou; Shintaro Iwama; Monica V Talor; Todd D Armstrong; Saskia J A M Santegoets; Susan F Slovin; Lei Zheng; Daniel A Laheru; Elizabeth M Jaffee; Winald R Gerritsen; Alfons J M van den Eertwegh; Dung T Le; Patrizio Caturegli
Journal:  Int J Cancer       Date:  2014-05-28       Impact factor: 7.396

Review 9.  Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Front Immunol       Date:  2017-05-09       Impact factor: 7.561

10.  Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.

Authors:  A H Honkoop; K Hoekman; J Wagstaff; C J van Groeningen; J B Vermorken; E Boven; H M Pinedo
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.